Phenotypes CoLaus

B: Base 2003-2008 **F1:** Followup 2009-2013 **F2:** Followup 2014-2018 **F3:** Followup 2018-2021

Interview

Age, gender, origin, ethnicity (up to grandparents)	B	F1	F2	F3
Education level, occupation, socio-economic status	B	F1	F2	F3
Smoking, alcohol intake, physical activity	B	F1	F2	F3
Personal history of CVD, hypertension, diabetes, stroke, myocardial infarction, and coronary procedures or surgery.	B	F1	F2	F3
Current medication (over the counter or prescription)	B	F1	F2	F3
Screen for cognitive disorders (Mini-Mental State Evaluation: MMSE; in subjects ≥ 65 years)	B	F1	F2	F3
Familial history of CVRF or CVD	B			
Service utilization			F2	F3
Health economic data				F3

Physical exam

Height, weight, waist and hip circumference, blood pressure, heart rate, percent fat (bio impedance), hand grip	B	F1	F2	F3

Blood (fasting)

Markers of diabetes and insulin resistance:				
glucose, insulin, leptin, adiponectin	B	F1	F2	F3
HbA1c			F2	F3
Makers of dyslipidemia:				
total, HDL and LDL-cholesterol, triglycerides, LDL-size[1], ApoB[1]	B	F1	F2	F3
Lp(a), ApoA-IV		F1		
Markers associated with increased CVD risk:				
ultra-sensitive CRP, homocystein[1], NT-pro BNP	B	F1	F2	F3
TNFa[2], IL-6[2], Il-1b[2]	B	F1	F2	F3
High sensitivity Troponin T			F2	F3

CoLaus Study, CHUV
Rue du Bugnon 19
1011 Lausanne
Switzerland
Phone: +41 21 314 73 61
Fax: +41 21 314 80 37
research.colaus@chuv.ch

PsyCoLaus Study, CHUV
CEPP, Route de Cery 25
1008 Prilly
Switzerland
Phone: +41 21 314 35 52
Fax: +41 21 314 84 69
research.psycolaus@chuv.ch

FNSNF
Fonds national suisse
Schweizerischer Nationalfonds
Fondo nazionale svizzero
Swiss National Science Foundation

CHUV Centre hospitalier universitaire vaud

Markers of co-morbid conditions:				
liver function tests: ASAT, ALAT, g-GT, alkaline phosphatase	B	F1	F2	F3
renal function: creatinine, urea	B	F1	F2	F3
chronic elevated alcohol consumption: carbohydrate deficient transferin[1]	B	F1	F2	F3
others: uric acid, calcium, albumin[1], total proteins	B	F1	F2	F3
blood count		F1	F2	F3
iron status (iron, transferin, ferritin),	B		F2	F3
Vitamine D, Metabolome (n=835) by nuclear magnetic resonance (NMR)	B			

Urine

Microalbuminuria, Creatinine	B	F1	F2	F3
Electrolytes (Na+, K+, Mg++, Ca++, phosphate), uric acid and osmolarity	B			
Uromodulin	B			
Metabolome (n=835) by NMR and tandem mass spectrometry (MS/MS)	B			

DNA

Genotyping (500K SNP) imputed to 30,061,896 SNPs using 1000 Genome data	B			
Full exome sequencing of 500 subjects	B			
Exome sequencing of 200 selected genes in 2000 subjects	B			
Whole blood collected for additional DNA extraction	B	F1	F2	F3
or epigenetic analyses			F2	F3

Self-ratings

Psychopathology screening (General Health Questionnaire: GHQ-12)	B			
Depression screening (CES-D), dietary habits, physical activity (**see ActiLaus**), sleep patterns and disorders (**see HypnoLaus**), persistent pain, depression state		F1	F2	F3
Physical health and a mental health summary score (The 12-item Short Form Health Survey (SF12)			F2	F3
Fatigue screening (Krupp fatigue severity scale, Chalder fatigue scale)			F2	F3

CoLaus Study, CHUV
Rue du Bugnon 19
1011 Lausanne
Switzerland
Phone: +41 21 314 73 61
Fax: +41 21 314 80 37
research.colaus@chuv.ch

PsyCoLaus Study, CHUV
CEPP, Route de Cery 25
1008 Prilly
Switzerland
Phone: +41 21 314 35 52
Fax: +41 21 314 84 69
research.psycolaus@chuv.ch

FNSNF
Fonds national suisse
Schweizerischer Nationalfonds
Fondo nazionale svizzero
Swiss National Science Foundation

CHUV Centre hospitalier universitaire vaud

Mortality and incident CVD

Continuous comparison between the CoLaus|PsyCoLaus database and the registry of inhabitants.	F1	F2	F3
Collection of information on CVD and cause of death from medical records or the Swiss National Death Registry and establishment of diagnoses of CVD by an adjudication committee according to international recommendations	F1	F2	F3

Additional phenotypes

Polysomnography (n=2214, **see HypnoLaus**)	F1		
Bone densitometry (women, n=1501, **see OsteoLaus**)	F1		
Whole Body composition (women, n=800, **see OsteoLaus**)	F1		
Daily salivary cortisol[3] (a-amylase (Autonomic nervous system function), 4 time points)	F1	F2	F3
Electrocardiogram (12 Lead)		F2	F3
Physical activity with wrist worn accelerometer, electronic daily monitoring of mood regulation and activity (**see ActiLaus**)		F2	F3
Pulmonary function test (spirometry, **see PneumoLaus**)		F2	F3
Heart rate variability			F3
Gut microbiota (stool material collection)			F3

Additional information
[1] only baseline; [2] retrospectively assessed for baseline; [3] during PsyColaus at F1
Dietary habits: Questionnaire alimentaire Bus Santé - food frequency questionnaire (FFQ).
Pain: Persistent pain and the TnsSofres questionnaire.

COMPLEMENTARY INFORMATION ON ASSESSEMENTS OF COLAUS|PSYCOLAUS here

CoLaus Study, CHUV
Rue du Bugnon 19
1011 Lausanne
Switzerland
Phone: +41 21 314 73 61
Fax: +41 21 314 80 37
research.colaus@chuv.ch

PsyCoLaus Study, CHUV
CEPP, Route de Cery 25
1008 Prilly
Switzerland
Phone: +41 21 314 35 52
Fax: +41 21 314 84 69
research.psycolaus@chuv.ch

FNSNF
Fonds national suisse
Schweizerischer Nationalfonds
Fondo nazionale svizzero
Swiss National Science Foundation

CHUV Centre hospitalier universitaire vaud